Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer

<p>Multivariable Cox proportional hazards models for time to progression and time to death</p>

Đã lưu trong:

Chi tiết về thư mục
Tác giả chính:	Sofie H. Tolmeijer (15313251) (author)
Tác giả khác:	Emmy Boerrigter (15313254) (author), Takayuki Sumiyoshi (15034119) (author), Edmond M. Kwan (15313257) (author), Sarah W.S. Ng (14960841) (author), Matti Annala (15313260) (author), Gráinne Donnellan (15313263) (author), Cameron Herberts (14960820) (author), Guillemette E. Benoist (15313266) (author), Paul Hamberg (15313269) (author), Diederik M. Somford (15035198) (author), Inge M. van Oort (15035171) (author), Jack A. Schalken (15313272) (author), Niven Mehra (15011036) (author), Nielka P. van Erp (15313275) (author), Alexander W. Wyatt (14960922) (author)
Được phát hành:	2025
Những chủ đề:	Cancer Cancer Detection and Diagnosis Methods and Technology Biomarkers Circulating tumor cells/DNA/exosomes Genitourinary Cancers Prostate cancer Liquid Biopsy
Các nhãn:	Thêm thẻ Không có thẻ, Là người đầu tiên thẻ bản ghi này!

Những quyển sách tương tự

Supplementary Table S1 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Bằng: Sofie H. Tolmeijer (15313251)
Được phát hành: (2025)

Supplementary Table S2 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Bằng: Sofie H. Tolmeijer (15313251)
Được phát hành: (2025)

Supplementary Data 2 from Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study
Bằng: Ismael Fernández-Miranda (15051932)
Được phát hành: (2025)

Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Bằng: Andrew A. Davis (15030032)
Được phát hành: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
Bằng: Nam Q. Bui (14958210)
Được phát hành: (2025)

TS1-9 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
Bằng: Lavanya Sivapalan (15314248)
Được phát hành: (2025)

Supplemental Table 1 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
Bằng: Morten Lapin (15056728)
Được phát hành: (2025)

Supplemental Table 2 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
Bằng: Morten Lapin (15056728)
Được phát hành: (2025)

Supplemental Table 3 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
Bằng: Morten Lapin (15056728)
Được phát hành: (2025)

Supplementary Table S3 from Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma
Bằng: Jun Wang (15051911)
Được phát hành: (2025)

Supplementary Data 1 from Early Changes in Circulating Cell-Free <i>KRAS</i> G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
Bằng: Cloud P. Paweletz (14960112)
Được phát hành: (2025)

Supplementary Figure S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Bằng: Javier Pascual (15018176)
Được phát hành: (2025)

Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Bằng: Javier Pascual (15018176)
Được phát hành: (2025)

Supplementary Figure S3 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Bằng: Javier Pascual (15018176)
Được phát hành: (2025)

Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Bằng: Javier Pascual (15018176)
Được phát hành: (2025)

Supplementary Figure S5 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Bằng: Javier Pascual (15018176)
Được phát hành: (2025)

Supplementary Table S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Bằng: Javier Pascual (15018176)
Được phát hành: (2025)

Supplementary Table S3 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Bằng: Javier Pascual (15018176)
Được phát hành: (2025)

Supplementary Figure S7 from <i>NPY</i> Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
Bằng: Katleen Janssens (15053356)
Được phát hành: (2025)

Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Bằng: Stephanie Lheureux (16797697)
Được phát hành: (2025)

Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Bằng: Stephanie Lheureux (16797697)
Được phát hành: (2025)

Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Bằng: Stephanie Lheureux (16797697)
Được phát hành: (2025)

Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Bằng: Stephanie Lheureux (16797697)
Được phát hành: (2025)

Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Bằng: Stephanie Lheureux (16797697)
Được phát hành: (2025)

Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Bằng: Whitney L. Hensing (16461978)
Được phát hành: (2025)

Table S1-S8 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer
Bằng: Ruiyun Zhang (17142498)
Được phát hành: (2025)

Table S1 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
Bằng: N. Ari Wijetunga (15056183)
Được phát hành: (2025)

Table S2 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
Bằng: N. Ari Wijetunga (15056183)
Được phát hành: (2025)

Table S3 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
Bằng: N. Ari Wijetunga (15056183)
Được phát hành: (2025)

Table S4 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
Bằng: N. Ari Wijetunga (15056183)
Được phát hành: (2025)

Supplementary Figure S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Bằng: Kala Visvanathan (14952973)
Được phát hành: (2025)

Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Bằng: Kala Visvanathan (14952973)
Được phát hành: (2025)

Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Bằng: Kala Visvanathan (14952973)
Được phát hành: (2025)

Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Bằng: Kala Visvanathan (14952973)
Được phát hành: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Bằng: Kala Visvanathan (14952973)
Được phát hành: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
Bằng: Iris van 't Erve (15054503)
Được phát hành: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Bằng: Francesca Orzan (15055579)
Được phát hành: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Bằng: Francesca Orzan (15055579)
Được phát hành: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Bằng: Francesca Orzan (15055579)
Được phát hành: (2025)

Figure 1 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
Bằng: Martin Sjöström (14845882)
Được phát hành: (2025)

Cannot write session to /tmp/vufind_sessions/sess_7ql432b4dis5e9s2ogrmptbprt